Home > Insider Trading > Filing (0001140361-21-037657)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1865494	Io Biotech Inc.	IOBT	Pharmaceutical Preparations (2834)	870909276

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1890710	A. Claus Andersson	C/O Io Biotech, Inc. Ole Maaloes Veh 3 Copenhagen G7 2200		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-11-09	1,361,660	$0.00	1,361,660	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-11-09	354,830	$0.00	1,716,490	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-11-09	75,000	$14.00	1,791,490	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2021-11-09	147,881	$0.00	1,361,660	$0.00
Common Stock	Series C Preferred Stock	Disposition	2021-11-09	28,225	$0.00	354,830	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.
Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
Sunstone Life Science Ventures Fund III K/S ("Sunstone Fund III"). Sunstone LSV General Partner III ApS ("Sunstone LSV GP III") is the general partner of Sunstone Fund III and has voting and dispositive power over all of the shares of held by Sunstone Fund III. The reporting person is a General Partner of Sunstone Life Science Ventures A/S and a member of the executive board of Sunstone LSV GP III, and shares voting and dispositive power with respect to the shares held by Sunstone Fund III. The reporting person disclaims beneficial ownership of the shares held directly by Sunstone Fund III except to the extent of his pecuniary interest therein.